Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash & Equivalents (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Cash & Equivalents for 14 consecutive years, with $47.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 36.6% to $47.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.4 million through Dec 2025, down 36.6% year-over-year, with the annual reading at $67.1 million for FY2025, 43.67% down from the prior year.
  • Cash & Equivalents hit $47.4 million in Q4 2025 for Vistagen Therapeutics, down from $62.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $126.6 million in Q4 2023 to a low of $9.6 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $67.8 million across 5 years, with a median of $67.6 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 7508.91% in 2021 and later plummeted 81.53% in 2023.
  • Year by year, Cash & Equivalents stood at $83.7 million in 2021, then plummeted by 70.09% to $25.0 million in 2022, then soared by 405.48% to $126.6 million in 2023, then crashed by 40.96% to $74.7 million in 2024, then crashed by 36.6% to $47.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for VTGN at $47.4 million in Q4 2025, $62.8 million in Q3 2025, and $49.0 million in Q2 2025.